UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 511

Sortiert nach

Therapeutic Approaches to Bone Diseases

Science (American Association for the Advancement of Science), 2000-09, Vol.289 (5484), p.1508-1514

2000

Volltextzugriff (PDF)

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

Bone (New York, N.Y.), 2001-08, Vol.29 (2), p.185-191

2001

Volltextzugriff (PDF)

Bone density, strength, and formation in adult cathepsin K (−/−) mice

Bone (New York, N.Y.), 2009-02, Vol.44 (2), p.199-207

2009

Volltextzugriff (PDF)

Control of osteoblast function and regulation of bone mass

Nature (London), 2003-05, Vol.423 (6937), p.349-355

2003

Volltextzugriff (PDF)

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

Cell death and differentiation, 2003-10, Vol.10 (10), p.1165-1177

2003

Volltextzugriff (PDF)

Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis

Bone (New York, N.Y.), 2006-02, Vol.38 (2), p.234-243

2006

Volltextzugriff (PDF)

Alendronate Mechanism of Action: Geranylgeraniol, an Intermediate in the Mevalonate Pathway, Prevents Inhibition of Osteoclast Formation, Bone Resorption, and Kinase Activation in vitro

Proceedings of the National Academy of Sciences - PNAS, 1999-01, Vol.96 (1), p.133-138

1999

Volltextzugriff (PDF)

Mechanisms of action of bisphosphonates

Annual review of pharmacology and toxicology, 1998-01, Vol.38 (1), p.375-388

Rodan, G A

1998

Volltextzugriff (PDF)

Bisphosphonates: mechanisms of action

The Journal of clinical investigation, 1996-06, Vol.97 (12), p.2692-2696

1996

Volltextzugriff (PDF)

Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis

Bone (New York, N.Y.), 2001-12, Vol.29 (6), p.553-559

2001

Volltextzugriff (PDF)

Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol lipoproteins

Cell death and differentiation, 2004-07, Vol.11 (S1), p.S108-S118

2004

Volltextzugriff (PDF)

Bone Homeostasis

Proceedings of the National Academy of Sciences - PNAS, 1998-11, Vol.95 (23), p.13361-13362

Rodan, Gideon A.

1998

Volltextzugriff (PDF)

Integrin function in osteoclasts

Journal of endocrinology, 1997-09, Vol.154 Suppl, p.S47

1997

Volltextzugriff (PDF)

Bisphosphonate mechanism of action

Current molecular medicine, 2002-09, Vol.2 (6), p.571

2002

Volltextzugriff (PDF)

Bisphosphonate action : alendronate localization in rat bone and effects on osteoclast ultrastructure

The Journal of clinical investigation, 1991-12, Vol.88 (6), p.2095-2105

1991

Volltextzugriff (PDF)

Integrins and signaling in osteoclast function

Matrix Biology, 2000-05, Vol.19 (2), p.97-105

2000

Volltextzugriff (PDF)

Bone safety of long-term bisphosphonate treatment

Current medical research and opinion, 2004-08, Vol.20 (8), p.1291-1300

2004

Volltextzugriff (PDF)

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women

Current medical research and opinion, 2005-02, Vol.21 (2), p.185-194

2005

Volltextzugriff (PDF)

Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion

The EMBO journal, 1994-03, Vol.13 (5), p.1189-1196

1994

Volltextzugriff (PDF)

Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity

Prostaglandins, leukotrienes and essential fatty acids, 2006-08, Vol.75 (2), p.81-90

2006

Volltextzugriff (PDF)

Protein-Tyrosine Phosphatase Activity Regulates Osteoclast Formation and Function: Inhibition by Alendronate

Proceedings of the National Academy of Sciences - PNAS, 1996-04, Vol.93 (7), p.3068-3073

1996

Volltextzugriff (PDF)

Bone mass homeostasis and bisphosphonate action

Bone, 1997, Vol.20 (1), p.1-4

Rodan, G.A.

1997

Volltextzugriff (PDF)

Preservation of thoracic spine microarchitecture by alendronate: Comparison of histology and microCT

Bone (New York, N.Y.), 2006-03, Vol.38 (3), p.444-449

2006

Volltextzugriff (PDF)

High Fatty Acid Content in Rabbit Serum Is Responsible for the Differentiation of Osteoblasts Into Adipocyte‐like Cells

Journal of bone and mineral research, 1998-01, Vol.13 (1), p.96-106

1998

Volltextzugriff (PDF)

Nitrogen-containing bisphosphonate mechanism of action

Mini reviews in medicinal chemistry, 2004-09, Vol.4 (7), p.711

2004

Volltextzugriff (PDF)

1 – 25 von 511

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(480)
Mit Volltextzugriff
(449)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(300)
Life Sciences & Biomedicine
(276)
Animals
(241)
Humans
(177)
Rats
(120)
Biological And Medical Sciences
(109)
Male
(76)
Endocrinology & Metabolism
(75)
Female
(73)
Genetics & Heredity
(66)
Fundamental And Applied Biological Sciences. Psychology
(64)
Mice
(61)
Medical Sciences
(50)
Cell Line
(46)
Cells, Cultured
(46)
Biochemistry & Molecular Biology
(39)
Child
(38)
Cell Biology
(35)
Phenotype
(34)
Osteoclasts - Drug Effects
(33)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Therapeutic Approaches to Bone Diseases

Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women

Bone density, strength, and formation in adult cathepsin K (−/−) mice

Control of osteoblast function and regulation of bone mass

M-CSF, TNFα and RANK ligand promote osteoclast survival by signaling through mTOR/S6 kinase

Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis

Alendronate Mechanism of Action: Geranylgeraniol, an Intermediate in the Mevalonate Pathway, Prevents Inhibition of Osteoclast Formation, Bone Resorption, and Kinase Activation in vitro

Mechanisms of action of bisphosphonates

Bisphosphonates: mechanisms of action

Inhibition of bone resorption by alendronate and risedronate does not require osteoclast apoptosis

Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol lipoproteins

Bone Homeostasis

Integrin function in osteoclasts

Bisphosphonate mechanism of action

Bisphosphonate action : alendronate localization in rat bone and effects on osteoclast ultrastructure

Integrins and signaling in osteoclast function

Bone safety of long-term bisphosphonate treatment

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women

Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion

Prostaglandin E2 (PGE2) increases the number of rat bone marrow osteogenic stromal cells (BMSC) via binding the EP4 receptor, activating sphingosine kinase and inhibiting caspase activity

Protein-Tyrosine Phosphatase Activity Regulates Osteoclast Formation and Function: Inhibition by Alendronate

Bone mass homeostasis and bisphosphonate action

Preservation of thoracic spine microarchitecture by alendronate: Comparison of histology and microCT

High Fatty Acid Content in Rabbit Serum Is Responsible for the Differentiation of Osteoblasts Into Adipocyte‐like Cells

Nitrogen-containing bisphosphonate mechanism of action

Suchergebnisse filtern